The ANKIB1 Knockout Jurkat Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population of Jurkat cells with disruption of the ANKIB1 gene. This loss-of-function model enables study of the ANKIB1 E3 ubiquitin ligase in T lymphocyte biology. The polyclonal format provides a heterogeneous pool of edited cells, each carrying distinct mutations, offering a robust model free from clonal artifacts. These cells are ideal for dissecting ubiquitination-dependent processes in human T cells.
Jurkat cells are an immortalized human T lymphocyte line derived from a boy with acute T-cell leukemia. They serve as a classic model for T-cell signaling, apoptosis, and leukemia. Jurkat cells are well-suited for genetic manipulation and are used to study TCR signaling, NF-??B activation, and IL-2 production. This host background provides a physiological context for investigating ANKIB1’s role in T-cell pathways.
ANKIB1 is a RING-type E3 ubiquitin ligase that transfers ubiquitin from E2 enzymes to lysines on substrates, tagging them for proteasomal degradation by the 26S proteasome. It operates within the ubiquitin-proteasome system, alongside E1, E2, and deubiquitinases, controlling protein quality and potentially NF-??B signaling. Upstream regulators are not well-characterized, but downstream targets include proteins destined for degradation. By mediating polyubiquitination, ANKIB1 influences protein homeostasis and signaling.
In Jurkat T lymphocytes, ANKIB1 knockout enables dissection of E3 ligase function in T-cell biology. Loss of ANKIB1 may alter ubiquitination-dependent signaling, including NF-??B and TCR pathways, impacting apoptosis and cell cycle. The polyclonal knockout population is suited for bulk assays and screens, avoiding clonal bias, and allows global analysis of proteomic changes. This model is valuable for uncovering substrates and pathways in leukemia and immune regulation.
Applications include ubiquitination pathway analysis, substrate identification via ubiquitination IP and mass spectrometry, and functional assays such as IL-2 secretion measurement, NF-??B reporter assays, flow cytometry for apoptosis/cell cycle, and proteasome inhibition studies. These cells support research in protein quality control, hematological malignancies, and drug discovery. For further details, contact Ascent Research.
